Smart dosing of blood thinner could save kidneys in children

NCT ID NCT05672550

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tested a personalized way to dose the blood thinner enoxaparin in 50 children after kidney transplant. The goal was to prevent dangerous blood clots in the new kidney while avoiding excessive bleeding. Doctors used a computer model (Bayesian approach) to adjust doses based on each child's needs, aiming for a precise anti-Xa target. The trial compared this smart dosing to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enoxaparin (a blood thinner)
What this could lead to: If successful, this could lead to safer, more effective blood clot prevention in children after kidney transplant, reducing graft loss.
What could go wrong: This is a small, completed Phase 4 study with only 50 participants. The approach may not work for all children or may still carry bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS

Contacts and locations

Locations

CHU Félix Guyon

La Réunion, France
Hôpital Mère Enfant

Lyon, France
Hôpital Necker - Enfants malades

Paris, Île-de-France Region, 75015, France
Hôpital Necker Enfants Malades

Paris, 75015, France
Hôpital Pellegrin

Bordeaux, 33000, France
Hôpital Robert Debré

Paris, 75019, France
Hôpital de Hautepierre

Strasbourg, France
Hôpital de la Villeneuve

Montpellier, France
Hôpital des Enfants

Toulouse, France
Hôtel Dieu

Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.